Abstracts tagged "Cardiovascular"

Abstract Number: 0718 • ACR Convergence 2025
Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden
Hanna Lindberg¹, Klytaimnistra Voudouri¹, Lars Lindhagen¹, Maria K Svensson², Ann Knight¹ and Johanna Dahlqvist³, ¹Uppsala University, Uppsala, Sweden, ²Uppsala University, Uppsala, ³Uppsala University Hospital, Uppsala, Sweden
Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are rare yet severe autoimmune diseases. Previous studies have indicated that patients with AAV have an increased risk…
Abstract Number: 0522 • ACR Convergence 2025
The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
Abdulrahman Y Almansouri¹, Jiayi Li², Ali Alhadri³, Keith Colaco⁴, Paula Harvey⁵, Shadi Ahktari⁶, Vinod Chandran⁷, Dafna D. Gladman⁸, Richard Cook² and Lihi Eder⁷, ¹King Faisal Specialist Hospital and Research Centre, University of Toronto and Women's College Hospital, Toronto, Canada, ²University of Waterloo, Waterloo, Canada, ³King Fahad Hospital, University of Toronto and Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada, ⁴University of Toronto, Toronto, Canada, ⁵University of Toronto Department of Medicine and Women's College Hospital, Toronto, ON, Canada, ⁶University of Toronto Department of Medicine and Women's College Hospital, Toronto, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk of developing cardiovascular diseases, including arrhythmias. Given that traditional cardiovascular disease risk factors are prevalent…
Abstract Number: 0120 • ACR Convergence 2025
The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Emre Sahin¹, Maria Efthymiou², Danieli Andrade³, Megan Barber⁴, Maria Tektonidou⁵, Vittorio Pengo⁶, Massimo Radin⁷, Jose Pardos-Gea⁸, MARIA ANGELES AGUIRRE ZAMORANO⁹, Nina Kello¹⁰, Diana Paredes-Ruiz¹¹, H Michael Belmont¹², Paul Fortin¹³, Denis WAHL¹⁴, Ware Branch¹⁵, Maria Gerosa¹⁶, Guilherme Ramires de Jesus¹⁷, Zhuoli Zhang¹⁸, Tatsuya Atsumi¹⁹, Giulia Pazzola²⁰, Laura Andreoli²¹, Ali Duarte-Garcia²², Esther Rodriguez-Almaraz²³, Michelle Petri²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Guillermo Pons-Estel²⁷, Hui Shi²⁸, Jason S. Knight²⁹, Rohan Willis³⁰, Maria Laura Bertolaccini³¹, Hannah Cohen³² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²University College London, London, United Kingdom, ³University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵National and Kapodistrian University of Athens, Athens, Greece, ⁶Padova University Hospital, Padova, Italy, ⁷University of Turin, Turin, Turin, Italy, ⁸Vall d’Hebron University Hospital, Barcelona, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹⁰Northwell Health, Brooklyn, NY, ¹¹Biobizkaia Health Research Institute, Barakaldo, Spain, ¹²NYU School of Medicine, New York, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁴University of Lorraine, Nancy, France, ¹⁵University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁶University of Milan, Milano, Italy, ¹⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁸Peking University First Hospital, Beijing, Beijing, China (People's Republic), ¹⁹Hokkaido University, Sapporo, Japan, ²⁰Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²¹University of Brescia, Brescia, Brescia, Italy, ²²Mayo Clinic, Rochester, MN, ²³Hospital Universitario ¹² de Octubre, Madrid, Spain, ²⁴Johns Hopkins University School of Medicine, Timonium, MD, ²⁵Hospital Clinic Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul, Istanbul, Turkey, ²⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ²⁸Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic), ²⁹University of Michigan, Ann Arbor, MI, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹King's College London, London, United Kingdom, ³²University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Although antiphospholipid antibodies (aPL) are well-established risk factors for thrombosis, heritable thrombophilias (HT) are also associated with venous thromboembolism (VTE). The latter includes deficiencies…
Abstract Number: 2642 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). Inflammation is a driver of…
Abstract Number: 2317 • ACR Convergence 2025
Cardiovascular Risk and Psoriatic Arthritis Features: Dactylitis may Predict Cardiovascular Events
Roel Sanchez Baez¹, Katherine Benson¹, Arthur Kavanaugh² and Monica Guma¹, ¹University of California, San Diego, La Jolla, CA, ²Division of Rheumatology, Autoimmunity and Inflammation, UC San Diego School of Medicine, La Jolla, CA
Background/Purpose: Patients with PsA have an elevated risk of cardiovascular (CV) disease. We assessed whether specific PsA features may predict CV events among PsA patients.Methods:…
Abstract Number: 1779 • ACR Convergence 2025
Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium
Wenxian Zhou¹, Hannah Johnson², Michael Duryee², Engle Sharp², Carlos Hunter², Tate Johnson², Mabruka Alfaidi², Daniel Anderson³, Kishore Bidasee², Geoffrey Thiele² and Ted Mikuls², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE, ^30587964, Durham, NC
Background/Purpose: Endothelial cell (EC) dysfunction is a key driver of cardiovascular (CV) complications in rheumatoid arthritis (RA), yet mechanisms underlying EC dysfunction in RA are…
Abstract Number: 1427 • ACR Convergence 2025
Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Ricardo I. De la Rosa-Vazquez⁵, Victoria P. Limas-Martínez⁵, Annette Dominguez-Guerra⁵, Jesus Alberto Cardenas-de la Garza⁶, Iris J. Colunga-Pedraza³, Dionicio A. Galarza-Delgado³, Jose R Azpiri-Lopez⁷, Victor M Fraga-Enriquez⁸ and Diego Azamat Salcedo Almanza⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁸Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁹Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased cardiovascular (CV) risk due to a higher prevalence of comorbidities and chronic systemic inflammation. In those…
Abstract Number: 0709 • ACR Convergence 2025
Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
Tracy Frech¹, Venkateswara Gogulamudi², Denisse Moreno², Eric Austin¹, Charles Frech³, Anna Hemnes¹, Tania Ruiz¹, Alex Shahin¹, Megha Talati¹, Colin Maguire⁴ and Anthony Donato², ¹Vanderbilt University Medical Center, Nashville, TN, ²Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, ³Vanderbilt University, Nashville, TN, ⁴University of Utah, Salt Lake City, UT
Background/Purpose: Systemic sclerosis (SSc) disease models that faithfully recapitulate endothelial mediated vasculopathy are critical for testing and developing novel treatments. The generation of inducible pluripotential…
Abstract Number: 0502 • ACR Convergence 2025
Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Satani Sharkas¹, Saeed Abughazaleh² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Boston Medical Center - Brighton, Brighton, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are approved treatments for rheumatoid arthritis (RA). However, comparative safety data on cardiovascular outcomes and all-cause mortality…
Abstract Number: 0091 • ACR Convergence 2025
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Rheumatoid Arthritis: associations with treatment response and comorbidities
Athena Chin¹, susan branford², Annabelle Small³, malcolm Smith¹, monika Kutyna⁴, Robert King⁵, Susanna Proudman⁶, Devendra Hiwase⁷ and Mihir Wechalekar⁸, ¹Flinders Medical Centre, KURRALTA PARK, South Australia, Australia, ²SA Pathology, Adelaide, ³Flinders University, Bedford Park, South Australia, Australia, ⁴South Australian Health and Medical Research Institute, Adelaide, ⁵Flinders Medical Centre, Adelaide, South Australia, Australia, ⁶Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁷Royal Adelaide Hospital, Adelaide, ⁸Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is defined as the detection of recurrent somatic mutations, at a variant allele frequency (VAF) < ![if…
Abstract Number: 2607 • ACR Convergence 2025
ERS-RA as a Tool for Cardiovascular Risk Prediction in Established Rheumatoid Arthritis: An External Validation
Misti Paudel¹, Katherine Liao², Jon Giles³, Joan Bathon⁴, Hongshu Guan⁵, Brendan Everett⁶, Leah Santacroce⁷, Nancy Shadick⁸, Michael Weinblatt⁹, Pamela Rist⁶ and Daniel Solomon¹⁰, ¹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA, ³Cedars Sinai Medical Center, Los Angeles, CA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham & Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The Expanded Risk Model for Rheumatoid Arthritis (ERS-RA) incorporates traditional CV risk factors and RA-related measures of disease activity and has demonstrated better performance…
Abstract Number: 2276 • ACR Convergence 2025
Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
Jennifer Hanberg¹, David Cheng², Xuan Wang³, Rahul Sangar⁴, Yuk-Lam Ho⁴, Lauren Costa⁴, Rachael Matty⁴, Candace Feldman¹, Tate Johnson⁵, Joshua Baker⁶, Bryant England⁵, J. Michael Gaziano¹, Kelly Cho⁷, James O'Dell⁵, Grant Cannon⁸, Paul Monach⁴, Ted Mikuls⁵, Tianxi Cai⁷ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³University of Utah, Salt Lake City, UT, ⁴VA Boston Healthcare System, Boston, MA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Harvard Medical School, Boston, MA, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are often avoided when treating rheumatoid arthritis (RA) patients with decompensated heart failure (HF), based on increased rates of…
Abstract Number: 1774 • ACR Convergence 2025
Citrullinated and Malondialdehyde-Acetaldehyde Co-Modified Fibrinogen Activates Macrophages and Induces Pro-Fibrotic shift in Coronary Endothelium Phenotype
Nozima Aripova¹, Wenxian Zhou², Hannah Johnson¹, Michael Duryee¹, Kimberley Sinanan¹, Carlos Hunter¹, Tate Johnson¹, Mabruka Alfaidi¹, Daniel Anderson³, Kishore Bidasee¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ^30587964, Durham, NC
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for developing heart failure with preserved ejection fraction (HFpEF), which is characterized by impaired left ventricular…
Abstract Number: 1404 • ACR Convergence 2025
Higher cardiovascular risk and lymphoma development in primary Sjögren’s Syndrome with extraglandular involvement
Teresa Blázquez Sánchez¹, Antía García Fernández¹, Jorge Mairal Monesma², Arantxa Torres Roselló³, Elena Heras Recuero⁴, Raquel Largo Carazo⁵, Juan Antonio Martínez López⁶ and Miguel A. González-Gay⁷, ¹Fundacion Jiménez Díaz, Madrid, Madrid, Spain, ²Instituto de Investigacion Fundación Jiménez Díaz, Madrid, Spain, ³Fundacion Jiménez Díaz, Madrid, Spain, ⁴Hospital Fundacion Jimenez Dias, Madrid, Spain, ⁵Instituto de Investigacion Fundacion Jiménez Díaz, Madrid, Spain, ⁶Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain, ⁷Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: Primary Sjögren’s syndrome (pSS) can have a systemic involvement with extraglandular manifestations, which are associated with more severe disease and with higher risk of…
Abstract Number: 0695 • ACR Convergence 2025
Global Longitudinal, Circumferential, and Radial Strain in Systemic Sclerosis Patients with Left Ventricular Dysfunction
Jennifer Elise Abdalla¹, Yuichiro Okushi², Zoran Popovic², Heba Wassif² and Soumya Chatterjee³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, ³Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune rheumatologic disease characterized by fibrosis and vascular complications, which significantly impact various organs, including the heart. Cardiac…

« Previous Page
1
…
3
4
5
6
7
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].